Inventor
ADORANTE JOSEPH S
US26 patents
⚠️ This page may combine multiple inventors who share the name “ADORANTE JOSEPH S”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ALLERGAN INC
20 patentsUS5925342AJul 20, 1999
Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
ALLERGAN INC90 citations95
US5573758ANov 12, 1996
Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
ALLERGAN INC52 citations93
US7125908B2Oct 24, 2006
Treating pain using selective antagonists of persistent sodium current
ALLERGAN INC21 citations92
US7060723B2Jun 13, 2006
Treating neurological disorders using selective antagonists of persistent sodium current
ALLERGAN INC18 citations92
US5922746AJul 13, 1999
Inhibition of noninactivating Na channels of mammalian optic nerve as a means of preventing optic nerve degeneration associated with glaucoma
ALLERGAN INC27 citations92
US5705530AJan 6, 1998
Method for reducing intraocular pressure in the mammalian eye by administration of chloride channel blockers
ALLERGAN INC22 citations92
US5559151ASep 24, 1996
Method for reducing intraocular pressure in the mammalian eye by administration of chloride channel blockers
ALLERGAN INC20 citations92
US6991910B2Jan 31, 2006
High-throughput screen for identifying channel blockers that selectively distinguish transient from persistent sodium channels
ALLERGAN INC21 citations88
US8859780B2Oct 14, 2014
Benzimidazole derivatives as selective blockers of persistent sodium current
ALLERGAN INC7 citations76
US7767718B2Aug 3, 2010
Treating pain using selective antagonists of persistent sodium current
ALLERGAN INC7 citations73
US7754440B2Jul 13, 2010
High-throughput screen for identifying selective persistent sodium channels channel blockers
ALLERGAN INC5 citations73
US7705055B2Apr 27, 2010
Treating neurological disorders using selective antagonists of persistent sodium current
ALLERGAN INC4 citations73
US7361478B2Apr 22, 2008
High-throughput screen for identifying selective persistent sodium channels channel blockers
ALLERGAN INC7 citations73
US5891911AApr 6, 1999
Method for reducing intraocular pressure in the mammalian eye by administration of calcium chelators
ALLERGAN INC9 citations73
US7763651B2Jul 27, 2010
Treating pain using selective antagonists of persistent sodium current
ALLERGAN INC3 citations62
US5866605AFeb 2, 1999
Method for providing a neuroprotective effect to the mammalian eye by administration of chloride channel blockers
ALLERGAN INC2 citations62
US7728034B2Jun 1, 2010
Treating neurological disorders using selective antagonists of persistent sodium current
ALLERGAN INC0 citations52
US7723053B2May 25, 2010
High-throughput screen for identifying selective persistent sodium channels channel blockers
ALLERGAN INC0 citations51
US9540332B2Jan 10, 2017
Benzimidazole derivatives as selective blockers of persistent sodium current
ALLERGAN INC0 citations45
US6479458B1Nov 12, 2002
Targeting the reverse mode of the Na+/Ca2+ exchanger for the treatment of optic neuropathy associated with glaucoma and ischemic optic neuropathy
ALLERGAN INC1 citations45
ALLERGAN SALES INC
4 patentsUS6426358B1Jul 30, 2002
Inhibition of noninactivating Na channels of mammalian optic nerve as a means of preventing optic nerve degeneration associated with glaucoma
ALLERGAN SALES INC5 citations74
US6350780B1Feb 26, 2002
Methods and compositions for drug delivery
ALLERGAN SALES INC12 citations74
US6326389B1Dec 4, 2001
Inhibition of noninactivating Na channels of mammalian optic nerve as a means of preventing optic nerve degeneration associated with glaucoma
ALLERGAN SALES INC6 citations74
US6420402B2Jul 16, 2002
Inhibition of noninactivating Na channels of mammalian optic nerve as a means of preventing optic nerve degeneration associated with glaucoma
ALLERGAN SALES INC3 citations63